



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

31st Edition

M100

Performance Standards for Antimicrobial Susceptibility Testing

This document includes updated tables for the Clinical and Laboratory Standards Institute antimicrobial susceptibility testing standards M02, M07, and M11.

A CLSI supplement for global application.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Performance Standards for Antimicrobial Susceptibility Testing

Melvin P. Weinstein, MD
James S. Lewis II, PharmD, FIDSA
April M. Bobenchik, PhD, D(ABMM)
Shelley Campeau, PhD, D(ABMM)
Sharon K. Cullen, BS, RAC
Marcelo F. Galas
Howard Gold, MD, FIDSA
Romney M. Humphries, PhD, D(ABMM)

Thomas J. Kirn, Jr., MD, PhD
Brandi Limbago, PhD
Amy J. Mathers, MD, D(ABMM)
Tony Mazzulli, MD, FACP, FRCP(C)
Sandra S. Richter, MD, D(ABMM), FIDSA
Michael Satlin, MD, MS
Audrey N. Schuetz, MD, MPH, D(ABMM)
Patricia J. Simner, PhD, D(ABMM)

Abstract

The data in the tables are valid only if the methodologies in CLSI documents M02,¹ M07,² and M11³ are followed. These standards contain information about disk diffusion (M02¹) and dilution (M07² and M11³) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02,¹ M07,² and M11.³ Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*. 31st ed. CLSI supplement M100 (ISBN 978-1-68440-104-8 [Print]; ISBN 978-1-68440-105-5 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2021.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

**If you or your organization is not a member and would like to become one,
or to request a copy of the catalog, contact us at:**

P: +1.610.688.0100; **F:** +1.610.688.0700; **E:** customerservice@clsi.org; **W:** www.clsi.org.

Copyright ©2021 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*. 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute; 2021.

Previous Editions:

December 1986, December 1987, December 1991, December 1992, December 1994, December 1995, January 1997, January 1998, January 1999, January 2000, January 2001, January 2002, January 2003, January 2004, January 2005, January 2006, January 2007, January 2008, January 2009, January 2010, June 2010, January 2011, January 2012, January 2013, January 2014, January 2015, January 2016, January 2017, January 2018, January 2019, January 2020

M100-Ed31
ISBN 978-1-68440-104-8 (Print)
ISBN 978-1-68440-105-5 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 41, Number 3

Committee Membership

Subcommittee on Antimicrobial Susceptibility Testing

Melvin P. Weinstein, MD Chairholder Robert Wood Johnson University Hospital USA	Howard Gold, MD, FIDSA Beth Israel Deaconess Medical Center USA	Tony Mazzulli, MD, FACP, FRCP(C) Sinai Health System Canada
James S. Lewis II, PharmD, FIDSA Vice-Chairholder Oregon Health and Science University USA	Romney M. Humphries, PhD, D(ABMM) Vanderbilt University Medical Center USA	Sandra S. Richter, MD, D(ABMM), FIDSA bioMérieux USA
Sharon K. Cullen, BS, RAC Beckman Coulter, Inc., Microbiology Business USA	Thomas J. Kirn, Jr., MD, PhD Rutgers Robert Wood Johnson Medical School USA	Michael Satlin, MD, MS New York Presbyterian Hospital USA
Marcelo F. Galas Pan American Health Organization USA	Brandi Limbago, PhD Centers for Disease Control and Prevention USA	Audrey N. Schuetz, MD, MPH, D(ABMM) Mayo Clinic USA
	Amy J. Mathers, MD, D(ABMM) University of Virginia Medical Center USA	Patricia J. Simner, PhD, D(ABMM) Johns Hopkins School of Medicine, Department of Pathology USA

Acknowledgment

CLSI and the Subcommittee on Antimicrobial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to the revision of this document:

April M. Bobenchik, PhD, D(ABMM) Lifespan Academic Medical Center USA	Shelley Campeau, PhD, D(ABMM) Accelerate Diagnostics, Inc. USA
---	--

Working Group on AST Breakpoints

George M. Eliopoulos, MD
Co-Chairholder
Beth Israel Deaconess Medical
Center
USA

James S. Lewis II, PharmD, FIDSA
Co-Chairholder
Oregon Health and Science
University
USA

Michael Satlin, MD, MS
Co-Chairholder
New York Presbyterian Hospital
USA

Karen Bush, PhD
Committee Secretary
Indiana University
USA

Marcelo F. Galas
Pan American Health Organization
USA

Romney M. Humphries, PhD,
D(ABMM)
Vanderbilt University Medical Center
USA

Amy J. Mathers, MD, D(ABMM)
University of Virginia Medical Center
USA

Navaneeth Narayanan, PharmD, MPH
Ernest Mario School of Pharmacy,
Rutgers University
USA

Robin Patel, MD
Mayo Clinic
USA

Simone M. Shurland
FDA Center for Drug Evaluation
and Research
USA

Lauri D. Thrupp, MD
University of California Irvine
Medical Center
USA

Hui Wang, MD
Peking University People's Hospital
China

Barbara L. Zimmer, PhD
Beckman Coulter, Inc.
USA

Working Group on Methods Application and Interpretation

Thomas J. Kirn, Jr., MD, PhD
Co-Chairholder
Rutgers Robert Wood Johnson
Medical School
USA

Brandi Limbago, PhD
Co-Chairholder
Centers for Disease Control and
Prevention
USA

Kristie Johnson, PhD, D(ABMM)
Committee Secretary
University of Maryland, Baltimore
USA

Darcie E. Carpenter, PhD
International Health Management
Associates, Inc.
USA

Stephen G. Jenkins, PhD, D(ABMM),
F(AAM)
Weill Cornell Medicine
USA

Joseph Kuti, PharmD, FIDP
Hartford Hospital
USA

Samir Patel, PhD, FCCM, D(ABMM)
Public Health Ontario
Canada

Virginia M. Pierce, MD
Massachusetts General Hospital
USA

Sandra S. Richter, MD, D(ABMM),
FIDSA
bioMérieux
USA

Susan Sharp, PhD, D(ABMM),
F(AAM)
Copan Diagnostics, Inc.
USA

Patricia J. Simner, PhD, D(ABMM)
Johns Hopkins School of Medicine,
Department of Pathology
USA

Working Group on Methods Development and Standardization

Dwight J. Hardy, PhD
Co-Chairholder
University of Rochester Medical
Center
USA

Barbara L. Zimmer, PhD
Co-Chairholder
Beckman Coulter, Inc.
USA

Katherine Sei, BS
Committee Secretary
Beckman Coulter, Inc.
USA

Kevin Alby, PhD, D(ABMM)
UNC School of Medicine
USA

Susan Butler-Wu, PhD, D(ABMM),
SM(ASCP)
LACUSC Medical Center
USA

Jennifer Dien Bard, PhD, D(ABMM),
F(CCM)
Children's Hospital Los Angeles;
University of Southern California
USA

Tanis Dingle, PhD, D(ABMM),
FCCM
Alberta Precision
LaboratoriesCanada

German Esparza, MSc
Proasecal SAS Colombia
Colombia

Laura M. Koeth, MT(ASCP)
Laboratory Specialists, Inc.
USA

Ribhi M. Shawar, PhD, D(ABMM),
F(AAM)
FDA Center for Devices and
Radiological Health
USA

Working Group on Outreach

Janet A. Hindler, MCLS, MT(ASCP),
F(AAM)
Co-Chairholder
Los Angeles County Department of
Health
USA

Audrey N. Schuetz, MD, MPH,
D(ABMM)
Co-Chairholder
Mayo Clinic
USA

Stella Antonara, PhD, D(ABMM)
Committee Secretary
OhioHealth
USA

April Abbott, PhD, D(ABMM)
Deaconess Hospital Laboratory
USA

April M. Bobenchik, PhD, D(ABMM)
Lifespan Academic Medical Center
USA

Graeme Forrest, MBBS
Rush University Medical Center
USA

Romney M. Humphries, PhD,
D(ABMM)
Vanderbilt University Medical Center
USA

Shawn R. Lockhart, PhD, D(ABMM)
Centers for Disease Control and
Prevention
USA

Nicole Scangarella-Oman, MS, BS,
GlaxoSmithKline
USA

Paula M. Snippes Vagnone,
MT(ASCP)
Minnesota Department of Health
USA

Priyanka Uprety, MSPH, PhD,
D(ABMM)
Rutgers Robert Wood Johnson
Medical School
USA

Lars F. Westblade, PhD, D(ABMM)
New York Presbyterian Hospital -
Weill Cornell Campus
USA

Working Group on Quality Control

Sharon K. Cullen, BS, RAC
Co-Chairholder
Beckman Coulter, Inc.,
Microbiology Business
USA

Maria M. Traczewski, BS, MT(ASCP)
Co-Chairholder
The Clinical Microbiology Institute
USA

Michael D. Huband, BS
Committee Secretary
JMI Laboratories
USA

Alexandra Lynn Bryson, PhD, D(ABMM)
Virginia Commonwealth University
Health
USA

Patricia S. Conville, MS, MT(ASCP)
FDA Center for Devices and
Radiological Health
USA

Dana C. Dressel, BS, MT(ASCP)
International Health Management
Associates, Inc.
USA

Janet A. Hindler, MCLS, MT(ASCP),
F(AAM)
Los Angeles County Department of
Health
USA

David Lonsway, MMSc
Centers for Disease Control and
Prevention
USA

Erika Matuschek, PhD
EUCAST Development Laboratory
Sweden

Stephanie L. Mitchell, PhD,
D(ABMM)
UPMC/University of Pittsburgh
USA

David Paisey, BSc
Thermo Fisher Scientific
United Kingdom

Elizabeth Palavecino, MD
Wake Forest Baptist Medical
Center
USA

Chris Pillar, PhD
Microbiologics
USA

Susan Thomson
MAST Group
United Kingdom

Katherine Young, MS
Merck & Company, Inc.
USA

Working Group on Text and Tables

April M. Bobenchik, PhD, D(ABMM)
Co-Chairholder
Lifespan Academic Medical Center
USA

Shelley Campeau, PhD, D(ABMM)
Co-Chairholder
Accelerate Diagnostics, Inc.
USA

Carey-Ann Burnham, PhD, D(ABMM)
Committee Secretary
Washington University School of
Medicine
USA

Sukantha Chandrasekaran, PhD,
D(ABMM)
University of California
USA

Andrea L. Ferrell, MLS^{CM}(ASCP)
Becton Dickinson
USA

Janet A. Hindler, MCLS, MT(ASCP),
F(AAM)
Los Angeles County Department of
Health
USA

Melissa Jones, MT(ASCP), CLS
UNC Healthcare
USA

Jean B. Patel, PhD, D(ABMM)
Beckman Coulter
USA

L. Barth Reller, MD
Duke University School of Medicine
USA

Felicia Rice, MT(ASCP)
Mayo Clinic
USA

Flavia Rossi, MD, PhD
University of São Paulo
Brazil

Dale A. Schwab, PhD, D(ABMM)^{CM}
Quest Diagnostics Infectious
Disease
USA

Maria M. Traczewski, BS,
MT(ASCP)
The Clinical Microbiology Institute
USA

Nancy E. Watz, MS, MT(ASCP),
CLS
Stanford Health Care
USA

Staff

Clinical and Laboratory Standards
Institute
USA

Marcy L. Hackenbrack, MCM, M(ASCP)
Senior Project Manager

Christine Lam, MT(ASCP)
Project Manager

Megan L. Tertel, MA, ELS
Editorial Manager

Catherine E.M. Jenkins, ELS
Editor

Kristy L. Leirer, MS
Editor

Laura Martin
Editor

Contents

Abstract	i
Committee Membership.....	iii
Overview of Changes	xiv
CLSI Breakpoint Additions/Revisions Since 2010.....	xxiii
CLSI Archived Resources	xxviii
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges.....	xxix
CLSI Reference Methods vs Commercial Methods and CLSI vs US Food and Drug Administration Breakpoints.....	xxx
Subcommittee on Antimicrobial Susceptibility Testing Mission Statement.....	xxxi
Instructions for Use of Tables.....	1
References	18
Table 1A. Suggested Groupings of Antimicrobial Agents Approved by the US Food and Drug Administration for Clinical Use That Should Be Considered for Testing and Reporting on Nonfastidious Organisms by Microbiology Laboratories in the United States ..	20
Table 1B. Suggested Groupings of Antimicrobial Agents Approved by the US Food and Drug Administration for Clinical Use That Should Be Considered for Testing and Reporting on Fastidious Organisms by Microbiology Laboratories in the United States.....	26
Table 1C. Suggested Groupings of Antimicrobial Agents Approved by the US Food and Drug Administration for Clinical Use That Should Be Considered for Testing and Reporting on Anaerobic Organisms by Microbiology Laboratories in the United States.....	32
Table 2A. Zone Diameter and MIC Breakpoints for Enterobacterales	34
Table 2B-1. Zone Diameter and MIC Breakpoints for <i>Pseudomonas aeruginosa</i>	48
Table 2B-2. Zone Diameter and MIC Breakpoints for <i>Acinetobacter</i> spp.	52

Contents (Continued)

Table 2B-3. Zone Diameter and MIC Breakpoints for *Burkholderia cepacia* complex..... 56

Table 2B-4. Zone Diameter and MIC Breakpoints for *Stenotrophomonas maltophilia*..... 58

Table 2B-5. MIC Breakpoints for Other Non-Enterobacterales (Refer to General Comment 1) 60

Table 2C. Zone Diameter and MIC Breakpoints for *Staphylococcus* spp..... 64

Table 2D. Zone Diameter and MIC Breakpoints for *Enterococcus* spp. 76

Table 2E. Zone Diameter and MIC Breakpoints for *Haemophilus influenzae* and *Haemophilus parainfluenzae* 82

Table 2F. Zone Diameter and MIC Breakpoints for *Neisseria gonorrhoeae* 88

Table 2G. Zone Diameter and MIC Breakpoints for *Streptococcus pneumoniae* 92

Table 2H-1. Zone Diameter and MIC Breakpoints for *Streptococcus* spp. B-Hemolytic Group 98

Table 2H-2. Zone Diameter and MIC Breakpoints for *Streptococcus* spp. Viridans Group..... 102

Table 2I. Zone Diameter and MIC Breakpoints for *Neisseria meningitidis*..... 106

Table 2J. MIC Breakpoints for Anaerobes 110

Table 3A. Tests for Extended-Spectrum B-Lactamases in *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Escherichia coli*, and *Proteus mirabilis*..... 114

Introduction to Tables 3B and 3C. Tests for Carbapenemases in Enterobacterales and *Pseudomonas aeruginosa* 118

Table 3B. CarbaNP Test for Suspected Carbapenemase Production in Enterobacterales and *Pseudomonas aeruginosa* 120

Table 3B-1. Modifications of Table 3B When Using MIC Breakpoints for Carbapenems Described in M100-S20 (January 2010) 124

Contents (Continued)

Table 3C. Modified Carbapenem Inactivation Methods for Suspected Carbapenemase Production in Enterobacterales and <i>Pseudomonas aeruginosa</i>	128
Table 3C-1. Modifications of Table 3C When Using MIC Breakpoints for Carbapenems Described in M100-S20 (January 2010)	140
Table 3D. Tests for Colistin Resistance for Enterobacterales and <i>Pseudomonas aeruginosa</i>	142
Table 3E. Test for Performing Disk Diffusion Directly From Positive Blood Culture Broth	148
Table 3F. Test for Detection of β -Lactamase Production in <i>Staphylococcus</i> spp.	150
Table 3G-1. Test for Detecting Methicillin (Oxacillin) Resistance in <i>Staphylococcus aureus</i> and <i>Staphylococcus lugdunensis</i>	154
Table 3G-2. Test for Detecting Methicillin (Oxacillin) Resistance in <i>Staphylococcus</i> spp. Except <i>Staphylococcus aureus</i> and <i>Staphylococcus lugdunensis</i>	156
Table 3H. Vancomycin Agar Screen for <i>Staphylococcus aureus</i> and <i>Enterococcus</i> spp.	158
Table 3I. Test for Detecting Inducible Clindamycin Resistance in <i>Staphylococcus</i> spp., <i>Streptococcus pneumoniae</i> , and <i>Streptococcus</i> spp. B-Hemolytic Group	160
Table 3J. Test for Detecting High-Level Mupirocin Resistance in <i>Staphylococcus aureus</i>	164
Table 3K. Test for Detecting High-Level Aminoglycoside Resistance in <i>Enterococcus</i> spp. (Includes Disk Diffusion)	166
Table 4A-1. Disk Diffusion QC Ranges for Nonfastidious Organisms and Antimicrobial Agents Excluding β -Lactam Combination Agents	170
Table 4A-2. Disk Diffusion QC Ranges for Nonfastidious Organisms and β -Lactam Combination Agents	174
Table 4B. Disk Diffusion QC Ranges for Fastidious Organisms	178
Table 4C. Disk Diffusion Reference Guide to QC Frequency	182
Table 4D. Disk Diffusion Troubleshooting Guide	184

Contents (Continued)

Table 5A-1. MIC QC Ranges for Nonfastidious Organisms and Antimicrobial Agents Excluding β -Lactam Combination Agents	188
Table 5A-2. MIC QC Ranges for Nonfastidious Organisms and β -Lactam Combination Agents	194
Table 5B. MIC QC Ranges for Fastidious Organisms (Broth Dilution Methods)	198
Table 5C. MIC QC Ranges for <i>Neisseria gonorrhoeae</i> (Agar Dilution Method)	202
Table 5D. MIC QC Ranges for Anaerobes (Agar Dilution Method)	204
Table 5E. MIC QC Ranges for Anaerobes (Broth Microdilution Method)	206
Table 5F. MIC Reference Guide to QC Frequency	208
Table 5G. MIC Troubleshooting Guide	210
Table 6A. Solvents and Diluents for Preparing Stock Solutions of Antimicrobial Agents	214
Table 6B. Preparing Stock Solutions for Antimicrobial Agents Provided With Activity Expressed as Units	220
Table 6C. Preparing Solutions and Media Containing Combinations of Antimicrobial Agents	222
Table 7. Preparing Dilutions of Antimicrobial Agents to Be Used in Agar Dilution Susceptibility Tests	226
Table 8A. Preparing Dilutions of Antimicrobial Agents to Be Used in Broth Dilution Susceptibility Tests	228
Table 8B. Preparing Dilutions of Water-Insoluble Antimicrobial Agents to Be Used in Broth Dilution Susceptibility Tests	230
Appendix A. Suggestions for Confirming Antimicrobial Susceptibility Test Results and Organism Identification for Agents Approved by the US Food and Drug Administration for Clinical Use	232
Appendix B. Intrinsic Resistance	240
Appendix C. QC Strains for Antimicrobial Susceptibility Tests	248

Contents (Continued)

Appendix D. Anaerobe Cumulative Antibigram	254
Appendix E. Dosage Regimens Used to Establish Susceptible or Susceptible-Dose Dependent Breakpoints	260
Appendix F. Susceptible-Dose Dependent Interpretive Category	264
Appendix G. Epidemiological Cutoff Values	268
Appendix H. Using Molecular Assays for Resistance Detection	274
Appendix I. Cefiderocol Broth Preparation and Reading Broth Microdilution Minimal Inhibitory Concentration End Points	290
Glossary I (Part 1). β -Lactams: Class and Subclass Designations and Generic Names	296
Glossary I (Part 2). Non- β -Lactams: Class and Subclass Designations and Generic Names.....	300
Glossary II. Antimicrobial Agent Abbreviation(s), Route(s) of Administration, and Drug Class	304
Glossary III. List of Identical Abbreviations Used for More Than One Antimicrobial Agent in US Diagnostic Products	312
The Quality Management System Approach	314
Related CLSI Reference Materials	315